Express Pharma

CPhI conferences announces 5th Annual Pharma Pre-Connect Congress India

The Pharma Pre-Connect will offer opportunities to the Indian pharma and biopharma industry, as well as pharma manufacturers to push for new manufacturing practices and better visibility across the supply chain

0 213

CPhI Conferences has announced the 5th Annual Pharma Pre-Connect Congress India 2022, to be held on 28th November in Greater Noida.

Medicine spending in India and around the world is projected to grow in coming years, allowing Indian organisations to lead the sector and achieve a global leadership position. This will require a paradigm shift in the business model under which the industry operates. The industry needs to create models and initiatives to expand manufacturing capacity, invest in innovative technologies, focus on research and development, and distribution and export infrastructure.

The Pharma Pre-Connect will offer opportunities to the Indian pharma and biopharma industry, as well as pharma manufacturers to push for new manufacturing practices and better visibility across the supply chain.

CPhI’s 5th Annual Pharma Pre-Connect Congress India 2022 intends to touch upon the challenges and trends that will help innovate new products in India and enhance the manufacturing process and quality of products at par with international standards. It will discuss various aspects around regulations of biosimilars, R&D, clinical research, programme management and commercialisation for the pharma industry, among others. The congress will be a platform for industry experts and decision-makers to discuss pertinent trends in the pharma industry, deliberate on critical concerns the industry faces today and offer innovative solutions that will continue to place India on the roadmap to success in the pharma industry.

The congress will also have practical case study insights from Indian and international experts and panel discussions with a Q&A session. The series of panel discussions will include trending topics such as ‘Disrupting the pharmaceutical industr